Operaciones Relmada Therapeutics, Inc. - RLMD CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.06 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Relmada Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | 2.7 |
| Abrir* | 2.65 |
| Cambio de 1 año* | -85.24% |
| Rango del día* | 2.65 - 2.82 |
| Rango de 52 semanas | 1.81-38.68 |
| Volumen medio (10 días) | 134.05K |
| Volumen medio (3 meses) | 4.01M |
| Capitalización de mercado | 85.48M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 30.10M |
| Ingresos | N/A |
| EPS | -4.78 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 0.17 |
| Próxima fecha de resultados | Aug 9, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Jun 1, 2023 | 2.70 | -0.12 | -4.26% | 2.82 | 2.82 | 2.58 |
| May 31, 2023 | 2.79 | -0.15 | -5.10% | 2.94 | 3.02 | 2.74 |
| May 30, 2023 | 2.95 | 0.07 | 2.43% | 2.88 | 3.05 | 2.83 |
| May 26, 2023 | 2.91 | 0.15 | 5.43% | 2.76 | 2.93 | 2.76 |
| May 25, 2023 | 2.80 | -0.28 | -9.09% | 3.08 | 3.08 | 2.67 |
| May 24, 2023 | 3.07 | -0.06 | -1.92% | 3.13 | 3.17 | 2.88 |
| May 23, 2023 | 3.08 | -0.21 | -6.38% | 3.29 | 3.35 | 3.01 |
| May 22, 2023 | 3.29 | 0.21 | 6.82% | 3.08 | 3.31 | 3.08 |
| May 19, 2023 | 3.15 | 0.05 | 1.61% | 3.10 | 3.23 | 3.08 |
| May 18, 2023 | 3.08 | 0.09 | 3.01% | 2.99 | 3.11 | 2.98 |
| May 17, 2023 | 3.07 | 0.22 | 7.72% | 2.85 | 3.13 | 2.85 |
| May 16, 2023 | 2.90 | -0.07 | -2.36% | 2.97 | 3.00 | 2.85 |
| May 15, 2023 | 3.07 | 0.13 | 4.42% | 2.94 | 3.09 | 2.84 |
| May 12, 2023 | 2.95 | -0.13 | -4.22% | 3.08 | 3.09 | 2.93 |
| May 11, 2023 | 3.11 | -0.16 | -4.89% | 3.27 | 3.35 | 3.10 |
| May 10, 2023 | 3.23 | -0.11 | -3.29% | 3.34 | 3.36 | 3.14 |
| May 9, 2023 | 3.31 | -0.06 | -1.78% | 3.37 | 3.49 | 3.23 |
| May 8, 2023 | 3.49 | 0.35 | 11.15% | 3.14 | 3.69 | 3.13 |
| May 5, 2023 | 3.18 | 0.22 | 7.43% | 2.96 | 3.20 | 2.91 |
| May 4, 2023 | 3.02 | 0.39 | 14.83% | 2.63 | 3.04 | 2.63 |
Relmada Therapeutics, Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| Wednesday, August 9, 2023 | ||
| Hora (UTC) (UTC) 20:00 | País US
| Evento Q2 2023 Relmada Therapeutics Inc Earnings Release Q2 2023 Relmada Therapeutics Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 8, 2023 | ||
| Hora (UTC) (UTC) 10:59 | País US
| Evento Q3 2023 Relmada Therapeutics Inc Earnings Release Q3 2023 Relmada Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2019 | |
|---|---|---|---|---|---|
| Ingresos totales | 0 | 0 | 0 | 0 | 0 |
| Gastos totales de explotación | 161.249 | 125.703 | 60.8387 | 16.5024 | 8.27161 |
| Gastos de venta/general/administración Gastos, total | 47.9261 | 35.0819 | 24.8659 | 5.70317 | 4.758 |
| Investigación y desarrollo | 113.323 | 90.6216 | 35.9727 | 7.02475 | 3.51361 |
| Gastos (ingresos) extraordinarios | 3.77447 | 0 | |||
| Ingresos de explotación | -161.249 | -125.703 | -60.8387 | -16.5024 | -8.27161 |
| Ingresos por intereses (gastos), netos No operativos | -2.14635 | -0.04832 | 1.38228 | -0.81567 | 0.07506 |
| Gain (Loss) on Sale of Assets | |||||
| Otros, netos | 6.35161 | 0 | 0 | ||
| Ingresos netos antes de impuestos | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Ingresos netos después de impuestos | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Beneficio neto antes de partidas extra. Elementos | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Ingresos netos | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Beneficio neto diluido | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Promedio ponderado de acciones diluidas | 29.6287 | 17.5527 | 15.5942 | 6.31177 | 10.5779 |
| BPA diluido sin partidas extraordinarias | -5.3004 | -7.16423 | -3.81272 | -2.74377 | -0.77488 |
| BPA normalizado diluido | -5.3004 | -7.16423 | -3.81272 | -2.14577 | -0.77488 |
| Total de partidas extraordinarias | |||||
| Dividends per Share - Common Stock Primary Issue | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 0 | 0 | 0 | 0 | 0 |
| Gastos totales de explotación | 28.1536 | 38.7024 | 38.7372 | 45.5121 | 38.2974 |
| Gastos de venta/general/administración Gastos, total | 12.2926 | 11.8341 | 8.20805 | 14.5994 | 13.2846 |
| Investigación y desarrollo | 15.861 | 26.8684 | 30.5291 | 30.9127 | 25.0128 |
| Ingresos de explotación | -28.1536 | -38.7024 | -38.7372 | -45.5121 | -38.2974 |
| Ingresos por intereses (gastos), netos No operativos | 1.83203 | 0.75806 | -0.68155 | -0.7745 | -1.44836 |
| Ingresos netos antes de impuestos | -26.3216 | -37.9444 | -39.4187 | -39.935 | -39.7458 |
| Ingresos netos después de impuestos | -26.3216 | -37.9444 | -39.4187 | -39.935 | -39.7458 |
| Beneficio neto antes de partidas extra. Elementos | -26.3216 | -37.9444 | -39.4187 | -39.935 | -39.7458 |
| Ingresos netos | -26.3216 | -37.9444 | -39.4187 | -39.935 | -39.7458 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -26.3216 | -37.9444 | -39.4187 | -39.935 | -39.7458 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -26.3216 | -37.9444 | -39.4187 | -39.935 | -39.7458 |
| Beneficio neto diluido | -26.3216 | -37.9444 | -39.4187 | -39.935 | -39.7458 |
| Promedio ponderado de acciones diluidas | 30.0992 | 30.1041 | 30.0637 | 29.9359 | 28.3926 |
| BPA diluido sin partidas extraordinarias | -0.87449 | -1.26044 | -1.31117 | -1.33402 | -1.39986 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -0.87449 | -1.26044 | -1.31117 | -1.33402 | -1.39986 |
| Otros, netos | 0 | 0 | 6.35161 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2019 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 152.87 | 223.298 | 118.074 | 9.98438 | 116.94 |
| Efectivo e inversiones a corto plazo | 148.323 | 211.91 | 117.091 | 9.21655 | 116.443 |
| Efectivo y Equivalentes | 5.39591 | 44.4434 | 2.4954 | 9.21655 | 36.2785 |
| Total deudores, neto | 0.51243 | 0.08638 | 0.07946 | 0.24708 | 0.07309 |
| Prepaid Expenses | 4.03519 | 11.3015 | 0.90319 | 0.52075 | 0.42386 |
| Total Assets | 152.905 | 223.326 | 118.186 | 10.2197 | 117.136 |
| Property/Plant/Equipment, Total - Net | 0 | 0.00126 | 0.00721 | 0.005 | |
| Note Receivable - Long Term | 0 | 0.08638 | 0.20314 | 0.16583 | |
| Other Long Term Assets, Total | 0.03488 | 0.02829 | 0.025 | 0.025 | 0.025 |
| Total Current Liabilities | 12.4689 | 15.0609 | 12.6035 | 2.60642 | 1.45785 |
| Accounts Payable | 5.26194 | 11.1925 | 8.34648 | 0.92436 | 0.52266 |
| Accrued Expenses | 7.20694 | 3.86842 | 4.25698 | 1.31786 | 0.82494 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0.3642 | 0.11025 |
| Other Current Liabilities, Total | 0 | 0 | |||
| Total Liabilities | 12.4689 | 15.0609 | 12.6035 | 2.60642 | 1.45785 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | |||||
| Total Equity | 140.436 | 208.265 | 105.583 | 7.61332 | 115.678 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.0301 | 0.02774 | 0.01633 | 0.03898 | 0.01446 |
| Additional Paid-In Capital | 602.517 | 513.304 | 284.882 | 119.237 | 235.523 |
| Retained Earnings (Accumulated Deficit) | -462.111 | -305.067 | -179.315 | -111.662 | -119.859 |
| Total Liabilities & Shareholders’ Equity | 152.905 | 223.326 | 118.186 | 10.2197 | 117.136 |
| Total Common Shares Outstanding | 30.0992 | 27.7402 | 16.3329 | 9.74464 | 14.457 |
| Long Term Debt | 0 | 0 | |||
| Total Preferred Shares Outstanding | 0 | 0 | |||
| Inversiones a corto plazo | 142.927 | 167.466 | 114.596 | 80.1648 | |
| Property/Plant/Equipment, Total - Gross | 0.0167 | 0.0167 | 0.0167 | ||
| Accumulated Depreciation, Total | -0.0167 | -0.01544 | -0.0117 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 135.532 | 152.87 | 187.106 | 215.737 | 225.779 |
| Efectivo e inversiones a corto plazo | 132.442 | 148.323 | 184.152 | 211.955 | 220.65 |
| Efectivo y Equivalentes | 28.8944 | 5.39591 | 42.5244 | 37.2609 | 44.9344 |
| Inversiones a corto plazo | 103.548 | 142.927 | 141.628 | 174.694 | 175.716 |
| Total deudores, neto | 0 | 0.51243 | 0 | 0.04223 | 0.06545 |
| Prepaid Expenses | 3.08958 | 4.03519 | 2.95374 | 3.48374 | 5.06396 |
| Total Assets | 135.566 | 152.905 | 187.122 | 215.772 | 225.808 |
| Property/Plant/Equipment, Total - Net | |||||
| Property/Plant/Equipment, Total - Gross | |||||
| Accumulated Depreciation, Total | |||||
| Note Receivable - Long Term | |||||
| Other Long Term Assets, Total | 0.03488 | 0.03488 | 0.0161 | 0.03524 | 0.02829 |
| Total Current Liabilities | 10.0973 | 12.4689 | 20.7771 | 18.9212 | 15.4095 |
| Accounts Payable | 4.42197 | 5.26194 | 10.4258 | 7.53969 | 10.6701 |
| Accrued Expenses | 5.67529 | 7.20694 | 10.3513 | 11.3815 | 4.73933 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 10.0973 | 12.4689 | 20.7771 | 18.9212 | 15.4095 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 125.469 | 140.436 | 166.345 | 196.851 | 210.398 |
| Common Stock | 0.0301 | 0.0301 | 0.02864 | 0.03003 | 0.0294 |
| Additional Paid-In Capital | 613.872 | 602.517 | 590.483 | 581.569 | 555.182 |
| Retained Earnings (Accumulated Deficit) | -488.432 | -462.111 | -424.167 | -384.748 | -344.813 |
| Total Liabilities & Shareholders’ Equity | 135.566 | 152.905 | 187.122 | 215.772 | 225.808 |
| Total Common Shares Outstanding | 30.0992 | 30.0992 | 28.642 | 30.0246 | 29.4028 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets, Total | 0.25619 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2019 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -157.044 | -125.752 | -59.4564 | -17.3181 | -8.19654 |
| Efectivo de actividades de explotación | -103.802 | -91.8734 | -27.8088 | -10.4979 | -6.41378 |
| Efectivo de actividades de explotación | 0 | 0.00126 | 0.00375 | 0.00487 | 0.0022 |
| Partidas no monetarias | 42.6489 | 41.7419 | 20.7942 | 5.30986 | 2.367 |
| Cash Taxes Paid | 0 | 0 | 0 | ||
| Intereses pagados en efectivo | 0 | 0.00242 | 0.00593 | 0.00461 | |
| Cambios en el capital circulante | 10.5933 | -7.86471 | 10.8496 | 1.50548 | -0.58643 |
| Efectivo de actividades de inversión | 19.7336 | -54.118 | -34.4477 | 0 | -80.1648 |
| Gastos de capital | 0 | 0 | |||
| Efectivo procedente de actividades de financiación | 45.0205 | 187.939 | 28.4733 | 17.4755 | 113.641 |
| Emisión (amortización) de deuda, neta | 0 | -0.11025 | -0.28517 | -0.25396 | |
| Variación neta de la tesorería | -39.0475 | 41.948 | -33.7831 | 6.97761 | 27.062 |
| Emisión (retiro) de acciones, neto | 44.6468 | 187.939 | 28.5836 | 17.7606 | 113.895 |
| Otras partidas de flujo de caja de inversión, total | 19.7336 | -54.118 | -34.4477 | -80.1648 | |
| Elementos de flujo de caja de financiación | 0.37363 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -26.3216 | -157.044 | -119.099 | -79.6807 | -39.7458 |
| Cash From Operating Activities | -16.5051 | -103.802 | -67.9187 | -41.0559 | -19.4297 |
| Cash From Operating Activities | 0 | 0 | 0 | 0 | 0 |
| Non-Cash Items | 10.7301 | 42.6489 | 37.0181 | 20.8142 | 13.709 |
| Cash Taxes Paid | 0 | 0 | |||
| Cash Interest Paid | 0 | 0 | |||
| Changes in Working Capital | -0.91358 | 10.5933 | 14.1626 | 17.8106 | 6.60705 |
| Cash From Investing Activities | 40.0036 | 19.7336 | 21.3891 | -10.1682 | -10.0277 |
| Other Investing Cash Flow Items, Total | 40.0036 | 19.7336 | 21.3891 | -10.1682 | -10.0277 |
| Cash From Financing Activities | 0 | 45.0205 | 44.6106 | 44.0415 | 29.9484 |
| Issuance (Retirement) of Stock, Net | 0 | 44.6468 | 44.6106 | 44.0415 | 29.9484 |
| Issuance (Retirement) of Debt, Net | |||||
| Net Change in Cash | 23.4985 | -39.0475 | -1.91907 | -7.18257 | 0.49094 |
| Financing Cash Flow Items | 0.37363 |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| Deep Track Capital LP | Hedge Fund | 9.4282 | 2837818 | 0 | 2023-03-31 | HIGH |
| RTW Investments L.P. | Investment Advisor/Hedge Fund | 7.0827 | 2131835 | 64011 | 2023-03-31 | LOW |
| Kotler (Kevin) | Individual Investor | 6.3122 | 1899930 | 1899930 | 2022-12-12 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.6319 | 1695150 | -23813 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.0001 | 1504979 | -12001 | 2023-03-31 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 4.0579 | 1221399 | 121060 | 2023-03-31 | MED |
| Two Sigma Investments, LP | Hedge Fund | 2.5312 | 761875 | -88387 | 2023-03-31 | HIGH |
| Parsons Capital Management, Inc. | Investment Advisor | 2.3993 | 722166 | 225912 | 2023-03-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 2.2261 | 670033 | 401017 | 2023-03-31 | HIGH |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.8309 | 551096 | 55363 | 2023-03-31 | LOW |
| Palo Alto Investors LP | Hedge Fund | 1.801 | 542100 | 542100 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.669 | 502343 | 16092 | 2023-03-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.0405 | 313175 | 95365 | 2023-03-31 | HIGH |
| Mirae Asset Global Investments (USA) LLC | Investment Advisor | 0.96 | 288946 | 9531 | 2023-03-31 | LOW |
| Horizons ETFs Management (Canada) Inc. | Investment Advisor/Hedge Fund | 0.96 | 288945 | 0 | 2023-04-30 | MED |
| Walleye Capital LLC | Hedge Fund | 0.8721 | 262481 | -211202 | 2023-03-31 | LOW |
| Voloridge Investment Management, LLC | Investment Advisor/Hedge Fund | 0.8569 | 257923 | -75174 | 2023-03-31 | HIGH |
| Parametric Portfolio Associates LLC | Investment Advisor | 0.8565 | 257799 | -147669 | 2023-03-31 | LOW |
| DWS Investments UK Limited | Investment Advisor | 0.7939 | 238952 | 455 | 2023-03-31 | MED |
| Millennium Management LLC | Hedge Fund | 0.6722 | 202328 | -859446 | 2023-03-31 | HIGH |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group535K+
Traders
87K+
Clientes activos mensualmente
$113M+
Volumen mensual de inversión
$64M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Relmada Therapeutics, Inc. Company profile
Sobre Relmada Therapeutics Inc
Relmada Therapeutics, Inc. es una empresa de biotecnología en fase clínica. La empresa se centra en el desarrollo de la esmetadona (REL-1017), un antagonista del receptor de N-metil-D-aspartato (NMDA). Su producto candidato, la esmetadona, es una nueva entidad química (NCE) desarrollada como agente oral de acción rápida para el tratamiento de la depresión, las enfermedades del sistema nervioso central (SNC) y otras indicaciones potenciales. El REL-1017 es un bloqueador de los canales del receptor NMDA (NMDAR) que se dirige a los canales hiperactivos manteniendo la neurotransmisión glutamatérgica fisiológica. El programa clínico de la empresa para el REL-1017 evalúa su potencial como tratamiento antidepresivo de acción rápida, oral y una vez al día.
El precio actual de la acción Relmada Therapeutics, Inc. en tiempo real es 2.8 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: Norwood, Equillium, Inc., Ibstock PLC, ContourGlobal PLC, Dustin Group y J.B. Hunt Transport Services, Inc.. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
| Industry: | Bio Therapeutic Drugs |
2222 Ponce De Leon Blvd. 3Rd Floor
CORAL GABLES
FLORIDA 33134
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 535.000 traders de todo el mundo que eligen operar con Capital.com